A Phase 2 interventional study of PSMA PET/CT and Androgen Deprivation Therapy (ADT) +/- bicalutamide in Intermediate Risk Prostate Cancer, High Risk Prostate Cancer and Prostate Cancer, sponsored by Martin T. King, MD, PhD. Recruiting at 4 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-29.
Sponsored by Martin T. King, MD, PhD · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies testing bicalutamide in Prostatic Neoplasms — 5 open to participants now, 9 under way, 3 of them phase 3. bicalutamide · Prostatic Neoplasms.
Among the 55 studies testing bicalutamide in Prostatic Neoplasms, this one is the 41st largest by planned enrollment of the 54 interventional ones that give a count, is one of 4 that started in 2026, is one of 18 in phase 2, and was the 52nd registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →5 of the 55 studies testing bicalutamide in Prostatic Neoplasms are open now, in 3 countries. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18+ · Men only
Astellas Pharma Global Development, Inc. · Sites in Bulgaria
Ages 50–75 · Men only · Healthy volunteers
Baptist Health South Florida · Sites in United States
Ages 18+ · Men only
Marco Lorenzo Bonu · Sites in Italy
Ages 18–80 · Men only
By country, each count listing its studies:
bicalutamide: first FDA approval 1995 (CASODEX). What it is approved for, and how studies give it, is on its page →
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 21 · Phase 3 22 · Phase 4 5
First in 1994; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 23 is below the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 53 across the 54 interventional studies. Of the 42 that completed or were terminated, 10 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 55 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Martin T. King, MD, PhD as lead sponsor.
Martin T. King, MD, PhD has 1 study filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
4 of the studies testing bicalutamide in Prostatic Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00223145Phase 3Abdenour NabidStudy on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy Alone | 2026-12-31 |
| NCT07393867Martin T. King, MD, PhDAndrogen-responsive POSLUMA-guided Intra-prostatic Boost | 2026-12-15 |
| NCT07783282Astellas Pharma Global Development, Inc.A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate Cancer | 2027-04-30 |
| NCT04025372Brigham and Women's HospitalINTREPId (INTermediate Risk Erection PreservatIon Trial) | 2027-10-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 55 studies testing bicalutamide in Prostatic Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This research study is for men with intermediate- or high-risk prostate cancer who are planning to receive hormone therapy and radiation treatment. The purpose of the study is to see whether a special type of diagnostic imaging done during hormone therapy can help doctors more accurately target remaining cancer with radiation, while avoiding areas that may no longer need extra treatment. All participants will receive standard hormone therapy and radiation therapy, along with three imaging scans, over a six-month period. The information gained from this study may help make prostate cancer radiation treatment more precise and reduce side effects for future patients.
Prostate cancer is commonly treated with a combination of hormone therapy and radiation therapy. Hormone therapy, or androgen deprivation therapy (ADT), lowers testosterone levels and often shrinks or weakens prostate cancer before radiation begins. However, after hormone therapy starts, it can become harder for doctors to tell exactly where active cancer remains inside the prostate using standard imaging (typically an MRI). This study is being conducted to determine whether a newer imaging test can better identify which parts of the cancer are still active and may benefit from more focused radiation treatment.
All participants in this study will receive six months of ADT, which is part of standard care for intermediate- and high-risk prostate cancer. In addition, participants will undergo PSMA PET/CT scans, a type of imaging that highlights prostate cancer cells, as well as MRI scans. These scans will be performed at three time-points: before hormone therapy begins, approximately eight weeks after starting hormone therapy (before radiation planning), and again at 24 weeks (at the end of all treatment) to see how the cancer has responded to treatment.
Radiation therapy will begin shortly after the eight-week imaging scan. Participants will receive high-precision radiation (stereotactic body radiation therapy/SBRT) to the prostate over about two weeks. Based on the imaging results, doctors may give an extra "boost" of radiation to small areas that still show signs of active cancer. If the scans show that the cancer has responded well to hormone therapy, some patients may not need this extra boost. This approach is designed to deliver the strongest treatment where it is needed while limiting radiation to healthy tissue in order to minimize side effects.
The main goal of the study is to understand whether doctors can confidently use the mid-treatment PSMA PET/CT scan to guide radiation planning. Researchers will also monitor changes in PSA blood levels, imaging findings, treatment side effects, and patient-reported quality of life, including urinary, bowel, and sexual symptoms. Additionally, doctors participating in the study will provide feedback on how easy or difficult it is to define radiation target areas using the different scans.
Participation in this study lasts about 6 months, and all treatments provided are commonly used in prostate cancer care, with the incorporation of PSMA PET scans being the experimental component. While participants may or may not directly benefit, the results obtained from this study may help improve how radiation therapy is planned and delivered for future patients with prostate cancer, with the goal of maintaining treatment effectiveness while reducing side effects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
* ADT as prescribed * PSMA PET/CT imaging will be completed at baseline, 8 weeks after ADT start, and at end of treatment * SBRT is administered starting 10 weeks after ADT start
Diagnostic Test: PSMA PET/CT · Drug: Androgen Deprivation Therapy (ADT) +/- bicalutamide · Radiation: Stereotactic Body Radiation Therapy (SBRT) +/- focal microboost
PSMA PET/CT is an imaging test that uses a radioactive tracer to highlight prostate cancer cells. Imaging will be performed at baseline, approximately eight weeks after starting ADT, and approximately 24 weeks after starting ADT (end of treatment). These scans are used to guide radiation treatment planning and assess treatment response.
Drug page: BicalutamideStudies of BicalutamideBicalutamide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
ADT is used to lower testosterone levels, which can slow or shrink prostate tumors. All participants will receive approximately six months of ADT starting before radiation therapy, using injectable or oral medications. Depending on the type of ADT, participants may also receive daily bicalutamide. Bicalutamide is categorized as an antiandrogen, which means it will block the effects of testosterone and work together with ADT to slow down or shrink prostate cancer.
SBRT is a form of radiation therapy that delivers precise, high-dose radiation to the prostate over a short period of time. SBRT will be initiated 10 weeks after initiation of ADT and will be delivered in five sessions over two weeks. Based on PSMA PET/CT and MRI findings after initiation of ADT, some participants may receive an optional focal radiation microboost to areas of residual cancer. The microboost, if delivered, will be given during the same SBRT treatment sessions and will be limited by standard safety constraints.
Percentage of patients with GTV treatment contours that are highly concordant with GTV-combined interim.
To evaluate whether \>50% of patients will be treated utilizing GTV contours that are highly concordant with those from interim PET/MR scans (GTV-combined-interim) based on the dice coefficient
Time frame: 8 weeks from initiation of hormone therapy/before start of radiation therapy
Geometric accuracies of GTV-Combined-Baseline and GTV-combined-interim contours
The Dice coefficient of GTV-Combined-Baseline contours by the treating physician versus those independently drawn by the principal investigator will be calculated. The Dice coefficient of GTV-Combined-Interim contours by the treating physician versus those independently drawn by the principal investigator will also be calculated.
Time frame: 8 weeks from initiation of hormone therapy/before start of radiation therapy
PSA response
The median PSA values at 8-weeks and 24-weeks will be evaluated. The percentage of patients with a PSA≥0.1 ng/mL will be calculated.
Time frame: 8 weeks from initiation of hormone therapy and 24 weeks from initiation of hormone therapy (end of treatment)
PSMA PET response
PSMA-PET/CT response at 8-weeks and 24-weeks will be characterized utilizing PSMA PET RECIP 1.0 criteria. * Complete response: Absence of any PSMA uptake at interim PET. * Partial: 30% or greater decrease in PSMA-avid total tumor volume. * Progression: 20% or greater increase in total tumor volume. New PSMA-avid lesions will also count as progression. * Stable disease: Less than 30% decrease or less than 20% increase in total tumor volume.
Time frame: 8 weeks from initiation of hormone therapy and 24 weeks from initiation of hormone therapy (end of treatment)
MRI ADC contrast ratio
The ADC contrast ratio at baseline and 8-weeks will be calculated by evaluating the ratio of the mean ADC contrast within GTV-MRI against ADC contrast within a surrounding 2 mm ring.
Time frame: 8 weeks from initiation of hormone therapy
Started Apr 2026 (actual). Primary completion is estimated for Dec 2026, 7 months after the start.
Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 7 months is below that.
Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bicalutamide